LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article
NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article
RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article
Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.
Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.
Based on a new review, two conditions–one extremely common and the other rare–appear to be related to herbicide exposure during the Vietnam War era.
Both general medicine physicians and specialists can find interstitial lung disease (ILD) and pulmonary fibrosis confusing, according to a recent study.
Genetic and environmental risk factors have been associated with the development of multiple primary melanomas (MPM) but a new study questioned whether those patients might have increased predisposition to developing internal malignancies.
Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.
Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?
With increased imaging now detecting lung cancer nodules in sicker patients, a new report suggested that guidelines should be more directive in how to maximize benefit and minimize harm, while taking into account comorbidities and life expectancy.
Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.
Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.
Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.
A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.
An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.
Metformin, a commonly used drug for patients with Type 2 diabetes mellitus (DM), has shown promise in helping to treat prostate cancer (PCa), according to a new study.
The VA is taking a leading role in use of conservative treatment for veterans diagnosed with non-aggressive prostate cancer.
A recently launched VA study of mortality in Vietnam veterans will examine whether exposure to liver flukes, a parasitic worm, increased the risk of cholangiocarcinoma or bile duct cancer in those veterans.
Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer/T-cell neoplasms in the United States.
Prevention of AIDS-defining cancers, such as non-Hodgkin lymphoma, can be helped by early, sustained antiretroviral therapy, which results in long-term viral suppression, a new study found.
About a third of hematologic cancer patients in a recent cohort study screened positive for executive dysfunction, and more than 17% had memory problems.
Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).
Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.
In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.
In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).
In March, then-VA Secretary David Shulkin, MD, announced at the annual Wharton Health Care Business Conference that the VA will have eliminated hepatitis C infections among all patients willing and able to be treated by next spring.
While many other cancers have seen dramatic improvement in outcomes in the past 20 years, pancreatic cancer remains one of the deadliest malignancies, regardless of stage at diagnosis, with an overall five-year survival rate of only 8%, according to the American Cancer Society.
Colonoscopy is heavily promoted in the VA healthcare system, and a new study sought to document its effect on colorectal cancer (CRC) mortality rates.
The standard of care for locoregionally advanced rectal cancer (LARC) in the United States usually involves adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME).
While suspected, the relationship between dietary and lifestyle risk factors and long-term mortality from colorectal cancer remains poorly understood, according to a new study.
Chances are, if you haven’t trained or practiced at the VA, you haven’t seen cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin lymphoma.
While the availability of novel therapies is making the future brighter for non-Hodgkin’s lymphoma (NHL) patients, new treatments also are coming on line for Hodgkin’s lymphoma, which is a hematological cancer distinct from NHL.
Because several studies have suggested it fails to increase overall survival (OS) despite prolonging progression-free survival (PFS), use of maintenance rituximab (MR) following chemoimmunotherapy in follicular lymphoma (FL) remains controversial.
Multiple organizations have recommended timely treatment for patients with lung cancer.
The treatment armamentarium for renal cell carcinoma and other genitourinary cancers continues to expand.
More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers.
While guidelines for multiple myeloma advise pharmacologic prophylaxis to prevent development of venous thromboembolism (VTE) in high-risk patients, current risk assessment tools differ in the factors considered indicative of high risk and in the patients determined to need preventive anticoagulation.
Researchers reported positive results today for phase IIb testing of a vaccine for high-risk melanoma patients.
Federal researchers reported updated results of trials of cabozantinib plus nivolumab with and without ipilimumab in patients with refractory metastatic urothelial carcinoma on Saturday at the 2018 American Society of Clinical Oncology Annual Meeting.
HOUSTON — For veterans with hepatocellular carcinoma (HCC), research presented today at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago offers encouraging the news. The study determined that a new tyrosine kinase... View Article
Bleomycin, the first line standard of care for Hodgkin lymphoma causes pulmonary events in some patients, but physicians have been uncertain how many patients are affected and how long they remain at risk.
Assessing tumor growth and regression to determine a treatment’s efficacy over time can be challenging on an individual basis.
Vitamin D deficiency doesn’t just increase the risk of osteoporosis and other bone disorders, it dramatically increases the risk of death in older cancer patients with solid tumors, according to researchers at the Central Texas Veterans Healthcare System in Temple, and the University of Texas MD Anderson Cancer Center in Houston.
Physicians and patients want to do everything possible to minimize the risk of breast cancer recurrence without incurring unnecessary toxicity from chemotherapy.
For the physicians treating men with non-metastatic castration resistant prostate cancer, knowing the risk of progression or death provides valuable information to guide the timing and selection of treatment.
Despite limited evidence to support the practice, testing for Helicobacter pylori (Hp) infection is recommended for work-up of unexplained iron deficiency anemia (IDA).
SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1
While increased use of stereotactic body radiation might have played a key role in doubling survival rates for early-stage non-small cell lung cancer (NSCLC) among veterans between 2001 and 2010 compared to conventional radiation, a new study confirms that isn’t always the best way to assure longer survival.
BEDFORD, MA—Active surveillance (AS) has been widely implemented at the VA as a standard of care for low-risk prostate cancer (PCa). A study in the American Journal of Managed Care posits, however, that patient characteristics such as... View Article
© 2000-2017. All Materials Copyright Marathon Medical Communications, Inc.